US Oncologist Survey: Optimizing Treatments for ER/PR Positive HER2/neu Negative Metastatic Breast Cancer


January 31, 2011
31 Pages - SKU: TAG6232436
License type:
Table of Contents Search inside this report Related Reports
Countries covered: United States

Patient specific case scenarios that unfold throughout the report, presented to 174 high-prescribing oncologists on ER/PR Positive HER2neu Negative Metastatic Breast Cancer for their open responses on clinical decisions, distributed and collected December 15, 2010 and January 10, 2011. Patient progression reveals decisions in treatment throughout patient stages, factors influencing their decisions, barriers to optimal care, and confidence in treatment.

Patient case highlights:

In treating an 85-year-old woman presenting with hip pain who was diagnosed with ER/PR positive HER2/neu negative metastatic breast cancer and who underwent a simple mastectomy, 9 of 10 oncologists would recommend xx….To treat her breast cancer, 5 in 10 oncologists would choose…

In a 60-year-old woman with diabetes, hypertension, renal insufficiency, and chronic obstructive pulmonary disease who found a lump in her breast and tests revealed metastatic lesions in ribs, spine, and femur initially treated with…

Data has been synthesized to show the highest reported responses, “other” responses, and direct quotes from the oncologists. This is the primary research for the oncology prescribing data that you are missing - directly from high-prescribing US oncologists on ER/PR Positive HER2neu Negative Metastatic Breast Cancer.

Treatment decisions for advanced stages of breast cancer are difficult to track as information quickly changes along with the introduction of new products that all have an impact oncologists’ choices. This report is part of a series of oncology reports that allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer.

This report allows you to:
  • Understand what occurs with actual patients
  • Access the most up-to-date prescribing trends
  • Gain actionable data for developing and improving your market strategies
  • Pinpoint needs of your target audience
  • Focus resources to maximize the effectiveness of your budget
  • Understand where your product fits
  • Understand where your competitor’s product fits
Two patient specific case scenarios that unfold throughout the report, presented to high-prescribing oncologists on ER/PR HER2/neu Negative Metastatic Breast Cancer for their clinical decisions. In a survey including 174 oncologists’ responses, for specified patient with ER/PR positive HER2/neu negative metastatic breast cancer with comorbidities, 6 in 10 oncologists would….


Additional Information

Report Excerpt

Introduction

Breast cancers are classified by whether or not they express the genes for estrogen receptor, progesterone receptor or human epidermal growth factor receptor 2 (HER2/neu). These three receptors are known to help the cancers develop, and the most successful breast cancer treatments are hormone-based drugs that directly target these receptors. Breast cancers that have spread to distant sites remain largely incurable; they are managed by various combinations of therapies. The goals of treatment are focused on prolonging overall survival without having a negative impact on quality of life. Optimizing treatment involves an individualized approach based on a number of factors, including previous regimens and responses to them, the specific tumor biology, growth rate of the disease, risks for toxicity, and patient preference and comorbidities. The relative benefits and toxicities of various regimens are important considerations.

The use of combination therapy versus monotherapy or sequential single agents remains a strongly debated issue. As evidence of the controversial nature of the treatment approaches, the FDA recently announced its decision recommending withdrawing Avastin (bevacizumab) as a treatment for breast cancer, although the decision is being appealed. Since there is currently no single standard of care for the management of metastatic breast cancers and since practice patterns vary widely, the purpose of this report is to provide updated data on how U.S. oncologists currently manage ER/PR positive HER2/neu negative metastatic breast cancer.
Executive Summary
Chapter 1: Introduction
Table 1. Treatment Options in Metastatic Breast Cancer
Chapter 2: Respondent Demographics
Table 2. Eligibility Criteria for Survey Participation
Figure 2.1 Gender of Survey Respondents
Figure 2.2 Years since Medical School Graduation
Figure 2.3 Practice Settings
Figure 2.4 Practices in NCI Cancer Centers
Figure 2.5 Geographic Settings
Figure 2.6 Survey Respondents by State’s Breast Cancer Mortality
Figure 2.7 Number of Physicians in Practice Groups
Figure 2.8 Minimal Acceptable Level of Evidence in Determining Treatment Regimen
Chapter 3: Patient with ER/PR Positive HER2/neu Negative Metastatic Breast Cancer
Confidence managing patient with ER/PR positive HER2/neu negative metastatic breast cancer
Figure 3.1
Other than analgesics, treatment of patient’s hip pain with ER/PR positive HER2/neu negative metastatic breast cancer
Figure 3.2
Treatment with ER/PR positive HER2/neu negative metastatic breast cancer
Figure 3.3
Factors influencing treatment choice with ER/PR positive HER2/neu negative metastatic breast cancer
Figure 3.4
Factors Influencing Treatment Choice with ER/PR positive HER2/neu Negative Metastatic Breast Cancer
Next systemic treatment choice with ER/PR positive HER2/neu negative metastatic breast cancer
Figure 3.5
Chapter 4: Patient with ER/PR Positive HER2/neu Negative Metastatic Breast Cancer with Comorbidities
Confidence managing patient with metastatic breast cancer with multiple comorbidities
Figure 4.1
Barriers to managing patient, metastatic breast cancer with multiple comorbidities
Figure 4.2
Treatment in addition to the aromatase inhibitor for patient’s metastatic breast cancer with multiple comorbidities
Figure 4.3
Next treatment regimen for progressive metastatic breast cancer with multiple comorbidities
Figure 4.4
Factors influencing treatment for progressive metastatic breast cancer with multiple comorbidities
Figure 4.5
Chapter 5: Summary
Appendix A: Survey Instrument

More Oncology/Hematology reports by The Assessment Group

US Market Changes in the Treatment of Advanced Melanoma by The Assessment Group
Progressively unfolding patient case scenarios were presented to 200 U.S. oncologists, who manage patients with advanced melanoma, to understand differences in clinical decisions and the ...
US Market Changes in the Treatment of Non-Hodgkin's Lymphoma by The Assessment Group
The purpose of this research study is to examine the current and evolving practice patterns of oncologists in managing advanced non-Hodgkin’s lymphoma. A survey ...
US Market Changes in the Treatment of Advanced Prostate Cancer by The Assessment Group
Progressively unfolding patient case scenarios were presented to 151 U.S. oncologists in a survey for their open-ended responses providing rich insight into their clinical decisions. ...
US Market Changes in the Treatment of Advanced Lung Cancer by The Assessment Group
The purpose of this study is to examine changes in the market for therapeutics used in the treatment of advanced lung cancer by examining longitudinal ...
See all reports like this >>

More United States Oncology/Hematology reports

US Cancer Diagnostics Market: Innovative Technologies and Emerging Business Opportunities by Venture Planning Group
This report contains 620 pages, 103 tables and presents a comprehensive analysis of the US cancer diagnostics market, including: Major issues pertaining to the US laboratory ...
US Proton Therapy Market Analysis to 2017 by RNCOS
According to most Oncologists, about 60% of all cancer patients undergo some sort of radiation therapy during their course of treatment. Despite advances in technology ...
United States Oncology Drug Delivery Preferences and Opportunities in Cancer Drug Delivery by Frost & Sullivan
Drug delivery is an important area of drug development in the pharmaceutical and biotechnology industry. In Oncology, developers are interested in understanding the opportunities and ...
The US Hematology Market: Instrument and Consumable Sales Forecasts by Market Segment, Key Supplier Shares by Venture Planning Group
This report provides an overview of the US hematology market, including sales and market shares of leading instrument and consumable suppliers, as well as test ...
See all reports like this >>

More United States reports

D&B Country RiskLine Report: The United States of America by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...
D&B Country Report: The United States of America by Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...
Country Report United States January 2011 by Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...
Coal - US - a snapshot (2010) by Mintel - Snapshots
Coal in US by Mintel Global Market Navigator provides you with annual year-end market size data, most recently updated in 2010. This market covers consumption ...
See all reports like this >>

 

Research assistance

We can help you find what you need. Call us or write us:
US: 800.298.5699
Int'l: +1.240.747.3093
Need help in your search?
 

Related Markets


Oncology/Hematology Reports

 
 

Share this report


Other tasks

 
 

Join Alert Me now!

Receive bi-weekly email alerts on new market research

Sign up today!